Europe PMC requires Javascript to function effectively.

Either your web browser doesn't support Javascript or it is currently turned off. In the latter case, please turn on Javascript support in your web browser and reload this page.

Search life-sciences literature (45,103,589 articles, preprints and more)

Search results

1-25 of 563 results

Sort by:

Relevance ^{Relevance: This is determined based on a ranking of criteria including term frequency, rarity of term, recency of article, whether there is a Title or Author field match, etc.}

Times cited

Date

1 2 3 Next ...

Editorial: Coronavirus disease (COVID-19): mechanistic basic, translational, and clinical research aimed at identification of effective preventive and therapeutic strategies.
Montuschi P, Uckun FM, Stewart AG, Patrignani P
Front Pharmacol, 14:1247765, 13 Jul 2023
Cited by: 0 articles | PMID: 37547326 | PMCID: PMC10402265
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Upregulated Expression of ERBB2/HER2 in Multiple Myeloma as a Predictor of Poor Survival Outcomes.
Uckun FM, Qazi S
Int J Mol Sci, 24(12):9943, 09 Jun 2023
Cited by: 1 article | PMID: 37373090 | PMCID: PMC10298070
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Upregulated Expression of ErbB1 in Diffuse Large B-Cell Lymphoma as a Predictor of Poor Overall Survival Outcome.
Qazi S, Uckun FM
J Pers Med, 13(5):770, 29 Apr 2023
Cited by: 0 articles | PMID: 37240940 | PMCID: PMC10221820
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
CD22 Exon 12 Deletion as an Independent Predictor of Poor Treatment Outcomes in B-ALL.
Qazi S, Uckun FM
Cancers (Basel), 15(5):1599, 04 Mar 2023
Cited by: 0 articles | PMID: 36900389 | PMCID: PMC10000517
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
High Intra-Tumor Transforming Growth Factor Beta 2 Level as a Predictor of Poor Treatment Outcomes in Pediatric Diffuse Intrinsic Pontine Glioma.
Uckun FM, Qazi S, Trieu V
Cancers (Basel), 15(6):1676, 09 Mar 2023
Cited by: 3 articles | PMID: 36980562 | PMCID: PMC10046593
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
SARS-CoV-2 Vaccine Efficacy in Patients with Hematologic Malignancies: Practical Points for Further Research.
Guven DC, Sahin TK, Akın S, Uckun FM
Oncologist, 27(11):e917-e918, 01 Nov 2022
Cited by: 1 article | PMID: 36005823 | PMCID: PMC9632303
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
ERBB1/EGFR and JAK3 Tyrosine Kinases as Potential Therapeutic Targets in High-Risk Multiple Myeloma.
Uckun FM, Qazi S
Onco (Basel), 2(4):282-304, 14 Oct 2022
Cited by: 3 articles | PMID: 36311273 | PMCID: PMC9610889
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Tyrosine kinases in KMT2A/MLL-rearranged acute leukemias as potential therapeutic targets to overcome cancer drug resistance.
Uckun FM, Qazi S
Cancer Drug Resist, 5(4):902-916, 09 Oct 2022
Cited by: 4 articles | PMID: 36627892 | PMCID: PMC9771742
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Evaluation of the potential of Rejuveinix plus dexamethasone against sepsis.
Uckun FM, Saeed M, Awili M, Ozercan IH, Qazi S, Lee C, Shibli A, Skolnick AW, Prusmack A, Varon J, Barrera CI, Orhan C, Volk M, Sahin K
Future Microbiol, 17:1217-1229, 02 Sep 2022
Cited by: 1 article | PMID: 36052743 | PMCID: PMC9443789
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
RJX Improves Wound Healing in Diabetic Rats.
Uckun FM, Orhan C, Tuzcu M, Durmus AS, Ozercan IH, Volk M, Sahin K
Front Endocrinol (Lausanne), 13:874291, 02 Jun 2022
Cited by: 2 articles | PMID: 35721744 | PMCID: PMC9201994
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Impact of Therapy in Patients with Hematologic Malignancies on Seroconversion Rates After SARS-CoV-2 Vaccination.
Guven DC, Sahin TK, Akın S, Uckun FM
Oncologist, 27(4):e357-e361, 01 Apr 2022
Cited by: 12 articles | PMID: 35274729 | PMCID: PMC8982368
Add to export list Review
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Clinical and Non-clinical Proof of Concept Supporting the Development of RJX As an Adjunct to Standard of Care Against Severe COVID-19
Uckun FM, Saeed M, Awili M, Ozercan IH, Qazi S, Lee C, Shibli A, Skolnick AW, Prusmack A, Varon J, Barrera CI, Orhan C, Volk M, Sahin K
medRxiv, 18 Feb 2022
Cited by: 0 articles | PPR: PPR455796
Add to export list Preprint
Cancer drug resistance in multiple myeloma.
Uckun FM
Cancer Drug Resist, 5(2):271-276, 25 Mar 2022
Cited by: 5 articles | PMID: 35800374 | PMCID: PMC9255243
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Post-hoc Analysis of Pharmacodynamics and Single-Agent Activity of CD3xCD123 Bispecific Antibody APVO436 in Relapsed/Refractory AML and MDS Resistant to HMA or Venetoclax Plus HMA.
Watts J, Lin TL, Mims A, Patel P, Lee C, Shahidzadeh A, Shami P, Cull E, Cogle CR, Wang E, Uckun FM
Front Oncol, 11:806243, 13 Jan 2022
Cited by: 2 articles | PMID: 35096610 | PMCID: PMC8793782
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Antibody Responses to COVID-19 Vaccination in Cancer: A Systematic Review.
Guven DC, Sahin TK, Kilickap S, Uckun FM
Front Oncol, 11:759108, 04 Nov 2021
Cited by: 21 articles | PMID: 34804957 | PMCID: PMC8599356
Add to export list Review
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Dual Targeting of Multiple Myeloma Stem Cells and Myeloid-Derived Suppressor Cells for Treatment of Chemotherapy-Resistant Multiple Myeloma.
Uckun FM
Front Oncol, 11:760382, 10 Nov 2021
Cited by: 8 articles | PMID: 34858838 | PMCID: PMC8631522
Add to export list Review
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Risk, Characteristics and Biomarkers of Cytokine Release Syndrome in Patients with Relapsed/Refractory AML or MDS Treated with CD3xCD123 Bispecific Antibody APVO436.
Uckun FM, Watts J, Mims AS, Patel P, Wang E, Shami PJ, Cull E, Lee C, Cogle CR, Lin TL
Cancers (Basel), 13(21):5287, 21 Oct 2021
Cited by: 3 articles | PMID: 34771451 | PMCID: PMC8582601
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
CD123-Directed Bispecific Antibodies for Targeting MDS Clones and Immunosuppressive Myeloid-Derived Suppressor Cells (MDSC) in High-Risk Adult MDS Patients.
Uckun FM, Watts J
Front Aging, 2:757276, 27 Sep 2021
Cited by: 3 articles | PMID: 35822053 | PMCID: PMC9261311
Add to export list Review
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
A Clinical Phase 1B Study of the CD3xCD123 Bispecific Antibody APVO436 in Patients with Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome.
Uckun FM, Lin TL, Mims AS, Patel P, Lee C, Shahidzadeh A, Shami PJ, Cull E, Cogle CR, Watts J
Cancers (Basel), 13(16):4113, 15 Aug 2021
Cited by: 18 articles | PMID: 34439266 | PMCID: PMC8394899
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Non-clinical safety profile and pharmacodynamics of two formulations of the anti-sepsis drug candidate Rejuveinix (RJX).
Uckun FM, Orhan C, Powell J, Sahin E, Ozercan IH, Volk M, Sahin K
Biomed Pharmacother, 141:111823, 17 Jun 2021
Cited by: 2 articles | PMID: 34147902
Add to export list
Targeting Solid Tumors With BTK Inhibitors.
Uckun FM, Venkatachalam T
Front Cell Dev Biol, 9:650414, 14 Apr 2021
Cited by: 9 articles | PMID: 33937249 | PMCID: PMC8079762
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Rejuveinix Mitigates Sepsis-Associated Oxidative Stress in the Brain: Clinical Impact Potential in COVID-19 and Nervous System Disorders
Uckun FM, Tuzcu M, Gitterle M, Volk M, Sahin K
Research Square, 13 May 2021
Cited by: 0 articles | PPR: PPR339364
Add to export list Preprint v1
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Overcoming the Immunosuppressive Tumor Microenvironment in Multiple Myeloma.
Uckun FM
Cancers (Basel), 13(9):2018, 22 Apr 2021
Cited by: 26 articles | PMID: 33922005 | PMCID: PMC8122391
Add to export list Review
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Repurposing Anti-Malaria Phytomedicine Artemisinin as a COVID-19 Drug.
Uckun FM, Saund S, Windlass H, Trieu V
Front Pharmacol, 12:649532, 19 Mar 2021
Cited by: 22 articles | PMID: 33815126 | PMCID: PMC8017220
Add to export list Review
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Rejuveinix Reverses Severe Inflammatory Lung Damage in a Mouse Model of Fatal Sepsis
Uckun FM, Ozercan IH, Orhan C, Gitterle M, Sahin K
bioRxiv, 02 Jan 2021
Cited by: 0 articles | PPR: PPR260178
Add to export list Preprint

1-25 of 563 results

1 2 3 Next ...

Search life-sciences literature (45,103,589 articles, preprints and more)

Search results

Editorial: Coronavirus disease (COVID-19): mechanistic basic, translational, and clinical research aimed at identification of effective preventive and therapeutic strategies.

Upregulated Expression of ERBB2/HER2 in Multiple Myeloma as a Predictor of Poor Survival Outcomes.

Upregulated Expression of ErbB1 in Diffuse Large B-Cell Lymphoma as a Predictor of Poor Overall Survival Outcome.

CD22 Exon 12 Deletion as an Independent Predictor of Poor Treatment Outcomes in B-ALL.

High Intra-Tumor Transforming Growth Factor Beta 2 Level as a Predictor of Poor Treatment Outcomes in Pediatric Diffuse Intrinsic Pontine Glioma.

SARS-CoV-2 Vaccine Efficacy in Patients with Hematologic Malignancies: Practical Points for Further Research.

ERBB1/EGFR and JAK3 Tyrosine Kinases as Potential Therapeutic Targets in High-Risk Multiple Myeloma.

Tyrosine kinases in KMT2A/MLL-rearranged acute leukemias as potential therapeutic targets to overcome cancer drug resistance.

Evaluation of the potential of Rejuveinix plus dexamethasone against sepsis.

RJX Improves Wound Healing in Diabetic Rats.

Impact of Therapy in Patients with Hematologic Malignancies on Seroconversion Rates After SARS-CoV-2 Vaccination.

Clinical and Non-clinical Proof of Concept Supporting the Development of RJX As an Adjunct to Standard of Care Against Severe COVID-19

Cancer drug resistance in multiple myeloma.

Post-hoc Analysis of Pharmacodynamics and Single-Agent Activity of CD3xCD123 Bispecific Antibody APVO436 in Relapsed/Refractory AML and MDS Resistant to HMA or Venetoclax Plus HMA.

Antibody Responses to COVID-19 Vaccination in Cancer: A Systematic Review.

Dual Targeting of Multiple Myeloma Stem Cells and Myeloid-Derived Suppressor Cells for Treatment of Chemotherapy-Resistant Multiple Myeloma.

Risk, Characteristics and Biomarkers of Cytokine Release Syndrome in Patients with Relapsed/Refractory AML or MDS Treated with CD3xCD123 Bispecific Antibody APVO436.

CD123-Directed Bispecific Antibodies for Targeting MDS Clones and Immunosuppressive Myeloid-Derived Suppressor Cells (MDSC) in High-Risk Adult MDS Patients.

A Clinical Phase 1B Study of the CD3xCD123 Bispecific Antibody APVO436 in Patients with Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome.

Non-clinical safety profile and pharmacodynamics of two formulations of the anti-sepsis drug candidate Rejuveinix (RJX).

Targeting Solid Tumors With BTK Inhibitors.

Rejuveinix Mitigates Sepsis-Associated Oxidative Stress in the Brain: Clinical Impact Potential in COVID-19 and Nervous System Disorders

Overcoming the Immunosuppressive Tumor Microenvironment in Multiple Myeloma.

Repurposing Anti-Malaria Phytomedicine Artemisinin as a COVID-19 Drug.

Rejuveinix Reverses Severe Inflammatory Lung Damage in a Mouse Model of Fatal Sepsis

Partnerships & funding